Dual antiplatelet therapy (DAPT) one month after angioplasty with Xience stent was approved in Europe for patients with high risk of bleeding. The CE Mark approval comes after studies Xience 28 and Xience 90 are published. Immediately after authorization, Abbot was fast to announce what they consider to be the shortest approved scheme with the most<a href="https://solaci.org/en/2021/04/26/xience-receives-ce-mark-for-short-and-ultrashort-dapt-schemes/" title="Read more" >...</a>
In patients undergoing ST elevation acute myocardial infarction (STEMI) receiving primary PCI, no significative differences between prasugrel and ticagrelor were found. However, the latter was associated to a significantly higher number of repeat MI when considered separately. Few studies have compared the efficacy and safety of the two most potent oral P2Y12 receptor inhibitors in<a href="https://solaci.org/en/2020/11/12/ticagrelor-or-prasugrel-in-st-elevation-mi/" title="Read more" >...</a>
Potent P2Y12 receptor inhibitors, such as prasugrel and ticagrelor, have been tested mainly in a setting of acute coronary syndromes. There is little evidence on stable patients, particularly for prasugrel. Designing a study with that purpose seemed challenging enough, but adding aspirin discontinuation in patients without a particularly high bleeding risk took this research to<a href="https://solaci.org/en/2020/11/10/angioplasty-in-aspirin-free-stable-patients-with-prasugrel-innovation-continues/" title="Read more" >...</a>
This meta-analysis to be published in J Am Cardiol supports the use of aspirin monotherapy (ASA) after transcatheter aortic valve replacement (TAVR). The use of aspirin alone is associated to less bleeding without increased ischemic events such as strokes or mortality. The combined outcomes of four studies, including the recently published POPular TAVI (cohort A),<a href="https://solaci.org/en/2020/10/07/post-tavr-asa-monotherapy-consolidates/" title="Read more" >...</a>
Aspirin discontinuation 1 to 3 months after angioplasty with continued P2Y12 inhibitor therapy reduces the bleeding risk without an increase in thrombotic events. This is also the case for patients admitted with acute coronary syndrome. Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor has been shown to reduce the risk of major events compared with<a href="https://solaci.org/en/2020/09/01/can-aspirin-use-be-interrupted-after-angioplasty/" title="Read more" >...</a>
In recent times, a lot has been said about reducing the duration or intensity of antiplatelet therapy following percutaneous coronary intervention (PCI) regardless initial indications. All evidence in support of these arguments might be failing to show the risk of non-culprit lesion events in patients with acute coronary syndromes (ACS). Potent and prolonged antithrombotic therapies<a href="https://solaci.org/en/2020/04/22/are-non-culprit-lesions-really-innocent/" title="Read more" >...</a>
In patients with peripheral artery disease undergoing revascularization, the combination of rivaroxaban (Xarelto) and low doses of aspirin are superior to aspirin alone in the prevention of acute low limb ischemic events, amputation, cardiovascular events and strokes. The outcomes of VOYAGER PAD add to the COMPASS outcomes, showing the combination of therapies can benefit risk<a href="https://solaci.org/en/2020/03/31/virtual-acc-2020-voyager-pad-rivaroxaban-superior-to-aspirin-in-preventing-events/" title="Read more" >...</a>
Intolerance to aspirin is relatively frequent and there is no other non-steroid anti-inflammatory medication to replace it. The new guidelines of chronic coronary syndromes make class IIb recommendations to use prasugrel or ticagrelor in aspirin-intolerant patients. This is not meant to replace dual antiaggregation therapy in aspirin intolerant patients, when needed; it is just a<a href="https://solaci.org/en/2020/03/02/alternatives-for-patients-allergic-to-aspirin/" title="Read more" >...</a>
This study findings confirm less bleeding at no extra cost of thrombotic events when aspirin is discontinued after an acute coronary syndrome (ACS). In the same line as the original TWILIGHT, this study focused on ACS patients alone (excluding STEMI) and confirmed that aspirin discontinuation after 3-month DAPT to continue with ticagrelor alone, reduced the<a href="https://solaci.org/en/2019/11/20/aha-2019-twilight-discontinue-aspirin-after-acute-coronary-syndrome/" title="Read more" >...</a>
Courtesy of SBHCI. The safety and efficacy of antithrombotic and antiplatelet treatments in patients with atrial fibrillation admitted with acute coronary syndrome (who receive medical treatment or angioplasty) may vary from that in patients undergoing elective treatment. At 14 days from elective angioplasty or hospitalization due to acute coronary syndrome, patients were randomized in a 2×2<a href="https://solaci.org/en/2019/09/30/tct-2019-augustus-acs-apixaban-vs-warfarin-and-aspirin-vs-placebo-in-af-and-acs/" title="Read more" >...</a>